Multi-Strain Probiotic Composition for Broad IBS Symptom Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for irritable bowel syndrome (IBS) are limited in their ability to effectively improve all major symptoms, particularly in subtypes like IBS-D and IBS-C, and there is a lack of a broad-acting probiotic composition that can address the severity and frequency of abdominal pain, flatulence, dissatisfaction with bowel habits, and quality of life interference.
Innovation Solution
A pharmaceutical composition comprising specific strains of probiotics, including Lactobacillus helveticus, Lacticaseibacillus rhamnosus, Lacticaseibacillus casei, Lactiplantibacillus plantarum, Lactococcus lactis, Bifidobacterium longum, Bifidobacterium bifidum, and Streptococcus thermophilus, which are administered to treat IBS, IBS-D, and IBS-C, leading to symptom improvement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional probiotic treatments are used, then some IBS symptoms may be improved, but they fail to effectively improve all major symptoms across different IBS subtypes
Solution Approach 1:
The patent combines multiple probiotic strains (Lactobacillus helveticus, Lacticaseibacillus rhamnosus, Lacticaseibacillus casei, Lactiplantibacillus plantarum, Lactococcus lactis, Bifidobacterium longum, Bifidobacterium bifidum, and Streptococcus thermophilus) into a single pharmaceutical composition. This merging of different probiotic strains creates a synergistic effect that addresses multiple IBS symptoms across different subtypes (IBS-D, IBS-C, and mixed IBS) more effectively than single-strain probiotics alone
Solution Approach 2:
The pharmaceutical composition is designed to be universal across different IBS subtypes by incorporating a diverse consortium of probiotic strains that can address various symptom profiles. The composition functions as a multi-functional treatment that can improve abdominal pain, bloating, bowel habits, and quality of life interference regardless of whether the patient has IBS-D, IBS-C, or mixed IBS
2Ease of manufacture
If single-strain probiotics are used, then the treatment is simple, but they lack broad activity to improve all major IBS symptoms
Solution Approach 1:
The patent merges multiple probiotic strains into a single pharmaceutical composition that maintains ease of administration (one capsule daily) while achieving comprehensive symptom improvement. The combination includes Lactobacillus helveticus, Lacticaseibacillus rhamnosus, Lacticaseibacillus casei, Lactiplantibacillus plantarum, Lactococcus lactis, Bifidobacterium longum, Bifidobacterium bifidum, and Streptococcus thermophilus, each contributing to different aspects of IBS symptom management
3Reliability
If multi-strain probiotic products are used, then they may be more effective than mono-strain products, but the diversity of products makes determining therapeutic value complex
Solution Approach 1:
The patent creates a universal multi-strain probiotic composition that addresses multiple IBS symptoms simultaneously across different subtypes. By standardizing the composition with specific strains (Lactobacillus helveticus, Lacticaseibacillus rhamnosus, Lacticaseibacillus casei, Lactiplantibacillus plantarum, Lactococcus lactis, Bifidobacterium longum, Bifidobacterium bifidum, and Streptococcus thermophilus) in defined proportions, it simplifies the evaluation of multi-strain probiotic effectiveness while maintaining broad therapeutic applicability
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a pharmaceutical composition for treating IBS.